VistaGen Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on innovative medicine for depression, cancer and diseases and disorders involving the central nervous system , has signed a Letter of Intent to enter into a Cooperative Research and Development Agreement with the National Institute of Mental Health , part of the National Institutes of Health , to collaborate on a NIMH-sponsored Phase 2 clinical study of VistaGen's lead drug candidate, AV-101, in Major Depressive Disorder, one of the most common mental disorders in the U.S. The parties anticipate completing the definitive CRADA in December and both commencing and completing the Phase 2 depression study in 2015.
http://ift.tt/1t1rW2l
http://ift.tt/1t1rW2l
No comments:
Post a Comment